Supprelin La

(Histrelin)

Phase 3Small molecule

UUniversity of New Hampshire

Supprelin La is one of 55 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Prostate AdenocarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

57 competitors in Prostate Adenocarcinoma

#DrugCompanyPhaseTrials

Lupron

Sun Pharmaceutical Industries, Inc.

Approved

3 2

Erleada

Johnson & Johnson

Approved

3 3

Nubeqa

Bayer

Approved

1 4

Xtandi

Astellas

Approved

1 5

Firmagon

Ferring

Approved

5 6

Casodex

IIstituto Clinico Humanitas

Approved

5 7

Thalomid

Nexavar

Jevtana

Verzenio

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Recurrent Castration-Sensitive Prostate Carcinoma

NCT06378866

Q4 2031

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT05050084

Q4 2038

Phase 3Active, not recruiting

Prostate Adenocarcinoma

NCT04513717

Clinical

Trials by Indication[1]

Prostate Adenocarcinoma2 trials

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruiting·NNRG Oncology·Phase 3·NCT04513717·2,753 enrolled

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruiting·NNRG Oncology·Phase 3·NCT05050084·2,050 enrolled

Central precocious puberty1 trial

Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Completed· Endo Pharmaceuticals logo

Endo Pharmaceuticals·Phase 3·NCT00779103·36 enrolled

Recurrent Castration-Sensitive Prostate Carcinoma1 trial

MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer

Recruiting·MMayo Clinic·Phase 2·NCT06378866·532 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 24, 1991

SUPPRELIN

NDA NDA019836

Oct 12, 2004

VANTAS

NDA NDA021732

May 3, 2007

SUPPRELIN LA

NDA NDA022058

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Histrelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Histrelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Histrelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022058). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Supprelin La. U.S. Food & Drug Administration.
[6]
SEC EDGAR — University of New Hampshire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of New Hampshire

Patent Landscape[5]

Patent #Expires

8062652Jun 16, 2026

Supprelin La

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q4 2031

Q4 2038

Trials by Indication[1]

Prostate Adenocarcinoma2 trials

Central precocious puberty1 trial

Recurrent Castration-Sensitive Prostate Carcinoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News